Table 1 Clinicopathological features of gastric cancer in young and middle-aged patients

Gender

<0.001

 male

115 (58.1)

895 (81.7)

 female

83 (41.9)

201 (18.3)

Comorbidity

<0.001

 Negative

189 (95.5)

829 (75.6)

 Positive

9 (4.5)

267 (24.4)

 Hypertension

0 (0.0)

153 (14.0)

<0.001

 Coronary heart disease

0 (0.0)

22 (2.0)

0.064

 Diabetes mellitus

2 (1.0)

53 (4.8)

0.014

 COPD^a

0 (0.0)

7 (0.6)

0.389

 Brain infarction

0 (0.0)

18 (1.6)

0.094

 Chronic hepatitis B

6 (3.0)

12 (1.1)

0.044

Tumor location

<0.001

 Upper

15 (7.6)

396 (36.1)

 Middle

58 (29.3)

242 (22.1)

 Lower

123 (62.1)

444 (40.5)

 whole

2 (1.0)

14 (1.3)

Tumor size

0.012

  < 5 cm

117 (59.1)

541 (49.4)

  ≥ 5 cm

81 (40.9)

555 (50.6)

Histologic type

<0.001

 Well differentiated

7 (3.5)

123 (11.2)

 Moderately differentiated

17 (8.6)

323 (29.5)

 Poorly differentiated

164 (82.8)

587 (53.6)

 Signet ring cell or mucinous

10 (5.1)

63 (5.7)

T status

0.012

 T1

51 (25.8)

192 (17.5)

 T2

31 (15.7)

168 (15.3)

 T3

72 (36.4)

390 (35.6)

 T4

44 (22.2)

346( 31.6)

N status

0.067

 N0

62 (31.3)

392 (35.8)

 N1

27 (13.6)

205 (18.7)

 N2

41 (20.7)

206 (18.8)

 N3

68 (34.3)

293 (26.7)

Tumor marker

 CEA

<0.001

 Positive

16 (8.1)

245(22.4)

 Negative

182 (91.9)

851 (77.6)

 AFP

0.007

 Positive

3 (1.5)

69 (6.3)

 Negative

195 (98.5)

1027 (93.7)

 CA19-9

0.020

 Positive

26 (13.1)

221 (20.2)

 Negative

172 (86.9)

875 (79.8)

 CA125

0.152

 Positive

14 (7.1)

51 (4.7)

 Negative

184 (92.9)

1045 (95.3)